NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
20 trialsNCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07001618 2026-04-03
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06875128 2026-03-13
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Delcath Systems Inc.
Phase 2 Recruiting
NCT07420439 2026-02-19
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06690840 2026-01-05
AZALEA
European Institute of Oncology
Phase 2 Recruiting
NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT04388839 2025-11-26
Evolutionary Therapy for Rhabdomyosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04759248 2025-09-09
ATREZZO
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT03482362 2025-08-03
EORTC1616
The Netherlands Cancer Institute
Phase 2 Completed
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT03414658 2025-07-02
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06533722 2025-06-10
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting